News & CommentAlzheimer's Research

Allen Roses: From 'Street Fighter' to Corporate Insider

+ See all authors and affiliations

Science  15 May 1998:
Vol. 280, Issue 5366, pp. 1001-1004
DOI: 10.1126/science.280.5366.1001

You are currently viewing the summary.

View Full Text

Summary

On 17 June, the British-based pharmaceutical giant Glaxo Wellcome named controversial Duke University neurologist Allen Roses head of its worldwide genetics research efforts, making him a member of an elite group of ex-academics running big industrial genetics programs. Roses now oversees a $50 million genetics budget, part of Glaxo's $2 billion annual R&D effort. In recent interviews with Science, Roses discussed his goals for genetics research at Glaxo and his battles with skeptics about his Alzheimer's work--battles that are legendary in the field and that say a great deal about the drive and approach that Roses brings to his new job.

Related Content